Thermo fisher receives fda approval for ngs-based companion diagnostic for new non-small cell lung cancer treatment

Carlsbad, calif.--(business wire)--thermo fisher scientific, the world leader in serving science, has received approval from the u.s. food and drug administration (fda) for its oncomine dx target test as a companion diagnostic (cdx) to identify patients who may be candidates for hernexeos® (zongertinib tablets), a tyrosine kinase inhibitor (tki), developed by boehringer ingelheim. the test allows clinicians and pathologists to assess if non-small cell lung cancer (nsclc) tumors harbor human epi.
TMO Ratings Summary
TMO Quant Ranking